1	Cheese consumption and risk of diabetic retinopathies: A Mendelian Randomization study
	· · · · · · · · · · · · · · · · · · ·

- 2 Short Title: Cheese and Diabetic Retinopathy
- 3 Zenan Lin, MD^{1,*}; Di Hu, MD, PhD^{2,*}; Junhong Jiang, MD, PhD¹; of The μ-Biomedical Data
- 4 Investigating Group (Mu-BioDig)
- 5 * Zenan Lin and Di Hu contributed equally to this paper and should be considered as joint first authors.
- 6
- 7 The affiliations of the authors:
- 8 1. Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School
- 9 of Medicine, Shanghai 200080, China.
- 10 2. Department of Ophthalmology, Children's Hospital of Fudan University, Shanghai 201102, China.
- 11
- 12 Correspondence should be addressed to:
- 13 Junhong Jiang, MD, PhD
- 14 Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of
- 15 Medicine, Shanghai 200080, China.
- 16 Email: junhongj@126.com or junhong.jiang@shgh.cn
- 17
- **Funding:** No fund was obtained for this work.
- 19

20 Acknowledgement

- 21 We want to thank to the UK biobank and FinnGen project as well as the participants who generously
- 22 made the GWAS summary statistics of cheese intake and diabetic retinopathies publicly available. No
- fund was obtained for this work.
- 24
- 25 **Declaration of Interest statement:** The authors have nothing to disclose.
- 26

27 Abstract

Objectives: Diabetic retinopathy (DR) is the leading cause of visual loss in working-age adults
 worldwide. Cheese is a widely consumed dairy product, and cheese intake has various health benefiting
 effects. This study aimed to use Mendelian randomization (MR) to investigate the impact of cheese

- 31 consumption on DR.
- Methods: The genome-wide association study (GWAS) summary statistic generated from 451486
 European descent was introduced to identify the valid instrumental variables (IVs) for cheese intake.
- 34 As the outcomes, the GWAS data of three outcome traits (DR, proliferative diabetic retinopathy or
- 35 PDR, diabetic maculopathy or DMP) were obtained from the FinnGen research project. Multivariable
- 36 MR (MVMR) analysis was also conducted to determine whether the causal associations were affected
- 37 by the common risk factors of DR, such as Body Mass Index, systolic blood pressure (SBP),
- 38 triglycerides (TG), HDL cholesterol and hemoglobin A1c (HbA1c) levels.
- **Results:** The cheese consumption (per 1-SD increase) was found to be associated with a decreased risk
- 40 of DR (OR=0.701, P =0.011), PDR (OR=0.671, P=0.020), and DMP (OR=0.357, P=0.001). The
- 41 MVMR analyses demonstrated that the TG level did not affect the causal associations with the
- 42 decreased risks of DR and PDR. The study on DMP proved that the causal relations were independent
- 43 from the effect of SBP, TG, and HbA1c levels.
- 44 Conclusions: Genetic evidence suggested that cheese consumption was causally associated with the
- 45 decreased risk of DR. Given widespread cheese consumption, this could have significant implications
- 46 for global health burdens from DR.
- 47 Keywords: Mendelian Randomization; diabetic retinopathy; cheese consumption; causality
- 48
- 49
- 50

51 1 Introduction

52 Diabetic retinopathy (DR), the leading cause of visual loss in working-age adults globally, is the most 53 common vascular complication in diabetes mellitus.¹ Proliferative diabetic retinopathy (PDR) and diabetic maculopathy (DMP) are the primarily vision-threatening stages of DR and lead to severe 54 visual impairment, substantially diminishing vision-related quality of life.² As the prevalence of 55 56 diabetes grows yearly, the number of people with DR and the associated healthcare burden are expected 57 to increase dramatically.³ Although DR can be treated by retinal laser photocoagulation, intravitreal injections, and vitrectomy; the efficacy of these strategies remains insufficient.^{4, 5} Therefore, to prevent 58 59 the onset of DR as well as to delay the progression from early DR to vision-threatening DR are 60 meaningful for alleviating the burden of DR-related blindness. Identifying causal and modifiable risk 61 factors for DR is crucial for providing preventive strategies.

Dietary factors are the key modifiable risk factors that play essential roles in the preventing and managing diabetes.^{6, 7} However, compared with diabetes, little is known about the role of diet in the onset and development of DR.⁸ Cheese is a staple dairy product that has been reported to be associated with a lower risk of diabetes.⁹ Recently, a large observational study on diabetic patients found that higher consumption of cheese may reduce the risk of DR progression.¹⁰ Nevertheless, due to the potential confounding and reverse causation from observational studies,¹¹ the causal relationship between cheese consumption and DR could not be concluded.

Mendelian randomization (MR) analysis is a powerful statistical method that exploits the random assortment of genetic variants during meiosis to assess the potential causal effect.^{11, 12} As an alternative to randomized clinical trials, MR analysis offers an opportunity to investigate the causal effect efficiently. It has become widely used to assess the causal associations of risk factors in diabetes.^{13, 14} To the best of our knowledge, so far no MR study has been conducted to investigate the causal role of cheese intake on DR.

75 2 Materials and methods

76 2.1 The genetic instrumental variables (IVs) for the consumption of cheese

In order to select the valid IVs for the consumption of cheese, the relevant genome-wide association
studies (GWAS) summary dataset of the UK Biobank was acquired and analyzed via the IEU Open
GWAS Project (<u>https://gwas.mrcieu.ac.uk/datasets/</u>, GWAS ID: ukb-b-1489).^{15, 16} The basic features of
the dataset were described in Table 1 and Figure 1.



81

82 Fig 1. The workflow describing the MR analysis on the causal association between cheese consumption

83 and DR risks.

84

85 According to the MR methodology, three key assumptions are: 1) the included IVs are robustly 86 associated with the exposure trait; 2) they are associated with the outcome only through the exposure; 3) 87 they are independent from the confounders. (See Figure 1.) In order to identify the independent SNPs, 88 we selected the SNPs with P values less than 5×10^{-8} for the linkage disequilibrium clumping (r² < 89 0.001 within 10000Kb, and using the 1000 Genomes Project Phase 3 (EUR) as the reference panel). 90 When duplicated SNPs were detected, the one with the lowest P value was retained. When the SNPs 91 were unavailable in the outcome's dataset, the proxy SNPs ($r^2 > 0.8$) were utilized for further analyses. 92 Finally, 64 IVs for cheese consumption were identified to be valid IVs. (See Supplementary Table S1.) 93 We calculated the F statistics to assess the association strength between each SNP and its corresponding 94 trait. The results indicated sufficient statistical power for all SNPs as their F statistics (see 95 Supplementary Table S1) were more significant than 10.¹⁷ The analyzing procedures were performed with the R (version 4.1.3) packages ieugwasr (version 0.1.5) and TwoSampleMR (version 0.5.6).¹⁵ 96

97 2.2 The basic information of three outcome datasets

98 The GWAS datasets for diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and 99 diabetic maculopathy (DMP) were from the Finnish biobank project FinnGen 100 (https://www.finngen.fi/fi). Their GWAS data was accessed via the platform of the IEU OpenGWAS 101 "finn-b-DM_RETINOPATHY", project (https://gwas.mrcieu.ac.uk/datasets, GWAS ID: "finn-b-DM_RETINA_PROLIF", "finn-b-DM_MACULOPATHY").15, 16 The characteristics of the 102 103 datasets were shown in Table 1 and Figure 1.

104 2.3 Univariable and multivariable MR analysis

105 In the univariable MR (UVMR) analysis, the IVW approach was chosen as the major method, and 106 other analytical tools such as the MR Egger, weighted median, weighted mode, simple mode, and 107 MR-PRESSO were conducted to evaluate the robustness of the results. Moreover, the multivariable 108 MR (MVMR) studies were introduced to explore the potential mechanism through which cheese 109 consumption may influence the DR risk. The common risk factors for DR such as Body Mass Index 110 (BMI), systolic blood pressure (SBP), triglyceride (TG), high-density lipoprotein (HDL) cholesterol, 111 low-density lipoprotein (LDL) cholesterol, and hemoglobin A1c (HbA1c) levels were introduced into 112 the MVMR analyses. The GWAS summary statistics of the common risk factors were acquired from 113 the platform of the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/datasets, GWAS ID: 114 "ukb-b-19953", "ieu-b-38", "ieu-b-111", "ieu-b-109", "ieu-b-110" and "ieu-b-103", respectively).

115 2.4 Statistical analysis

116Briefly, the IVW method was the major MR analytical tool, and complemented by other approaches117such as the MR-Egger, simple mode, weighted median, weighted mode, and MR-PRESSO. The118MVMR analysis was conducted to explore the potential mechanism through which the cheese intake119may function. All analyses were conducted with R packages MRPRESSO (version 1.0), ieugwasr120(version 0.1.5), and TwoSampleMR (version 0.5.6).^{15, 16, 18} A P value less than 0.05 was considered as121statistically significant.

122

 124 3 Results 125 3.1 The basic features of the included datasets for exposure and outcomes 126 Three GWAS datasets for the cheese consumption contained 9851867 SNPs' data covering more than 127 42000 European participants. (See Table 1. and Figure 1.) As described in the method's part, 64 IV 128 were regarded as valid IVs for cheese consumption. The data originated from the studies of the UK 	
 3.1 The basic features of the included datasets for exposure and outcomes Three GWAS datasets for the cheese consumption contained 9851867 SNPs' data covering more that 42000 European participants. (See Table 1. and Figure 1.) As described in the method's part, 64 IVs were regarded as valid IVs for cheese consumption. The data originated from the studies of the UK 	
126 Three GWAS datasets for the cheese consumption contained 9851867 SNPs' data covering more that 127 42000 European participants. (See Table 1. and Figure 1.) As described in the method's part, 64 IVs 128 were regarded as valid IVs for cheese consumption. The data originated from the studies of the UK	
 42000 European participants. (See Table 1. and Figure 1.) As described in the method's part, 64 IVs were regarded as valid IVs for cheese consumption. The data originated from the studies of the UK 	ı
128 were regarded as valid IVs for cheese consumption. The data originated from the studies of the UK	;
The state of the s	-
129 Biobank. Three DR-associated datasets from the FinnGen project were selected as the outcome cohorts	;
130 for further analyses. The sample sizes for DR, PDR, and DMP were 216666 (14584 cases and 202082	2
131 controls), 212889 (8681 cases and 204208 controls), and 213377 (1811 cases and 211566 controls)	,
132 respectively.	
133	

134 Table 1. The basic information of the datasets of exposures and outcomes

Categories	Traits	IVs	GWAS ID	SNPs	Source	Ethnics	Sample size	Cases/controls
Exposure	Cheese consumption	64	ukb-b-1489	9851867	UK Biobank	European	451486	/
		/	finn-b-DM_R					
Outcome	Diabetic retinopathy		ETINOPATH	16380459	FinnGen	European	216666	14584/ 202082
			Y					
		/	finn-b-DM_R					
	Proliferative diabetic retinopathy		ETINA_PRO	16380460	FinnGen	European	212889	8681/204208
			LIF					
		/	finn-b-DM_					
	Diabetic maculopathy		MACULOPA	16380450	FinnGen	European	213377	1811/211566
			THY					

Note: GWAS ID refers to the datasets archived in the IEU Open GWAS project.

135

136 3.2 The UVMR analysis from cheese consumption to the risks of three diabetic retinopathies

137 The results of IVW analyses suggested that a 1-SD increase in cheese consumption was causally 138 associated with a 29.9% decrease in the overall risk of DR (Odds ratio or OR=0.701, P = 0.011), a 32.9% 139 decrease in the PDR risk (OR=0.671, P =0.020) and a 64.3% decrease in the DMP risk (OR=0.357, P 140 =0.001). Consistently, the sensitivity studies using MR Egger, Simple mode, Weighted median, 141 Weighted mode, and MR-PRESSO also indicated cheese consumption to be a protective role for DR, 142 PDR, and DMP, though some of them were not statistically significant. (See Table 2. and Figure 2.) 143 While the P for Cochran's Q in the IVW analysis on DR was less than 0.05, no heterogeneities were 144 identified to exist in the studies on PDR (P for Cochran's Q=0.078) and DMP (P for Cochran's 145 Q=0.588). (See Table 2. And Figure 2.) No obvious directional pleiotropies were detected in three 146 exposure-outcome pairs since their Egger intercept terms were all centered at the origin (0.006 for DR, 147 0.001 for PDR, and -0.003 for DMP). Though the MR-PRESSO global studies also suggested no 148 influence for the pleiotropy was observed in the analyses on PDR (P-global=0.052) and DMP 149 (P-global=0.419), the investigation on DR implied a potential pleiotropy (P-global=0.038). The 150 Leave-one-out tests demonstrated that no single SNP could greatly influence the overall estimates. (See

- 151 Figure 2.)
- 152

153 Table 2. The MR analyses of the causal associations between the consumption of cheese and diabetic

154 retinopathies

Exposure-Outcome		MR analysis		Heterogeneity test		Pleiotropy		
pairs	Method -	OR (95% CI)	Р	Q	Р	Egger intercept	Р	<i>P</i> -global
	IVW	0.701 (0.534, 0.921)	0.011	80.454	0.033			
	MR Egger	0.489 (0.154, 1.551)	0.229	79.908	0.030	0.006	0.532	
	Simple mode	0.484 (0.191, 1.223)	0.130					
Cheese-DR	Weighted median	0.751 (0.524, 1.078)	0.121					
	Weighted mode	0.507 (0.231, 1.114)	0.096					
	MR-PRESSO (RAW)	0.717 (0.625, 0.821)	0.017					0.038
	IVW	0.671 (0.479, 0.939)	0.020	75.047	0.078			
	MR Egger	0.627 (0.151, 2.613)	0.524	75.035	0.066	0.001	0.924	
	Simple mode	0.698 (0.245, 1.989)	0.504					
Cheese-PDR	Weighted median	0.777 (0.499, 1.211)	0.265					
	Weighted mode	0.673 (0.292, 1.548)	0.355					
	MR-PRESSO (RAW)	0.708 (0.597, 0.840)	0.048					0.052
	IVW	0.357 (0.193, 0.662)	0.001	57.756	0.558			
	MR Egger	0.428 (0.032, 5.792)	0.526	57.737	0.522	-0.003	0.889	
Cheese-DMP	Simple mode	0.116 (0.011, 1.189)	0.075					
	Weighted median	0.515 (0.209, 1.272)	0.150					
	Weighted mode	0.745 (0.112, 4.949)	0.762					



158 Fig 2. (A) Scatter plots of the genetic risks of the consumption of cheese on DR; (B) Forest plot of the 159 Leave-one-out test on the MR study of DR; (C) Scatter plots of the genetic risks of the consumption of 160 cheese on PDR; (D) Forest plot of the Leave-one-out test on the MR study of PDR; (E) Scatter plots of 161 the genetic risks of the consumption of cheese on DMP; (F) Forest plot of the Leave-one-out test on the 162 MR study of DMP.

163 164

165 3.3 The MVMR analysis from the cheese consumption to the risk of three diabetic retinopathies

166 As the UVMR suggested the potential causal associations between the consumption of cheese and the 167 risk of three diabetic retinopathies, the MVMR was introduced to investigate the potential mechanisms 168 through which the exposure may influence the outcomes.

169 We found that the TG level did not affect the causal associations with the risks of DR and PDR. (See

170 Figure 3.) The study on DMP proved that the causal relationship was independent from the effect of

171 SBP, TG, and HbA1c levels. (See Figure 3.)

Δ		OR	95% CI	P value	
	Cheese on DR	0.701	0.536, 0.921	0.011	++++
	BMI adjusted	0.967	0.739, 1.265	0.805	H
	SBP adjusted	0.879	0.653, 1.182	0.393	HH-
	TG adjusted	0.596	0.411, 0.865	0.006	H-1-
	HDL adjusted	0.800	0.568, 1.126	0.200	H ++++
	LDL adjusted	0.994	0.568, 1.738	0.983	
	HbA1c adjusted	0.810	0.557, 1.176	0.268	0.0 0.5 1.0 1.5 2
В	Cheese on PDR BMI adjusted SBP adjusted TG adjusted HDL adjusted HDA1c adjusted	OR 0.871 0.928 0.839 0.572 0.840 0.961 0.741	95% Cl 0.479, 0.939 0.648, 1.327 0.564, 1.246 0.356, 0.919 0.554, 1.273 0.446, 2.070 0.462, 1.188	P value 0.020 0.681 0.384 0.021 0.411 0.919 0.216	
С	Cheese on DMP	OR 0.357	95% CI 0.193, 0.662	P value 0.001	
	SRD adjusted	0.900	0.426, 1.000	0.000	
	SBP adjusted	0.390	0.176, 0.863	0.020	
	IG adjusted	0.228	0.091, 0.5/1	0.002	
	HDL adjusted	0.404	0.177, 0.920	0.031	
	LDL adjusted	0.565	0.181, 1.761	0.325	
				the second se	

172

173 Fig 3. MVMR analyses of causal associations between cheese consumption and DR (A), PDR (B) and

174 DMP (C) adjusted for common risk factors.

175

176 4 Discussion

177 In this two-sample MR study, we explored the causal effects of cheese consumption on diabetic 178 retinopathies by leveraging large-scale GWAS data. This is the first study to show that consuming more 179 habitual cheese was associated with a lower risk of developing diabetic retinopathies, providing a 180 potential new treatment option for DR.

181 Cheese is one of the most popular dairy products in the world and contains lots of nutrients. In 182 recent years, numerous studies have been carried out to investigate the association between cheese consumption and diabetes risk. Their results revealed that eating cheese is inversely associated with 183 diabetes.¹⁹⁻²² For instance, a large prospective case-cohort study across 8 European countries found a 184 modest inverse association of cheese intake with diabetes.²⁰ In a systemic review and meta-analysis on 185 186 cohort studies, Aune and colleagues also identified the inverse association between cheese intake and the risk of type 2 diabetes.²¹ Interestingly, Von Post-Skagegard et al. reported that the protein in cheese 187 has much stronger and quicker-acting glucoregulatory effects than fish protein and plant protein.²² 188 189 Though previous works have implied the negative association between cheese consumption and 190 diabetes risk; there has been little research exploring the relationship between eating cheese and DR 191 risk. In this MR study, we confirmed that having cheese may be a protective factor for DR. This is in 192 agreement with the results of prior studies on diabetes.

193 Cheese includes abundant calcium, vitamin D, whey protein, and magnesium. Multiple studies 194 have demonstrated that all the substances as mentioned above are associated with reduced diabetes 195 risk.²³⁻²⁷ This may partially explain the negative correlation between eating cheese and diabetes risk.

196 Despite the numerous studies on diabetes, to be best of our knowledge, only one published 197 investigation has assessed the association between cheese intake and DR risk by observing the 10-year 198 incidence of DR in diabetic patients in Australia.²⁸ The study showed that cheese consumption could 199 diminish the risk of DR in diabetic patients. This conclusion stands in line with our current work.

200 Higher BMI, SBP, HbA1c, LDL, and HDL cholesterol levels were acknowledged as risk factors for DR.²⁹ Concurrently, these risk factors for DR are influenced by cheese intake: First, in systemic 201 parameters, cheese intake was shown to reduce BMI in a randomized controlled trial.³⁰ And a recent 202 203 MR report demonstrated that cheese consumption was causally associated with a lower BMI.³¹ Furthermore, the inverse correlation between SBP and cheese intake has also been reported.³² Secondly, 204 205 among circulating metabolites, HbA1c has been confirmed by a large RCT meta-analysis to be 206 negatively associated with dairy product intake like cheese.³³ Moreover, multiple RCTs showed that cheese intake could decrease the levels of LDL cholesterol concentration,^{34, 35} and increase the 207 208 HDL-cholesterol concentration levels significantly.³⁶ In concordance with those of previous studies, 209 our MVMR results indicated that cheese consumption might function to protect DR by affecting these 210 risk factors (see Figure 4). On the other hand, cheese consumption has been proven to be able to alleviate the oxidative stress³⁷ and inflammatory response,³⁸ which are the significant factors in the 211 initiation and progression of DR.^{39,40} This may also be one of the underlying mechanisms that cheese 212 213 consumption suppresses DR (see Figure 4).



214

Fig 4. Diagram showing the possible mechanism by which cheese consumption reduces the risk of DR.216

Though our work confirmed the causality between cheese consumption and DR risk through the MR framework, it is still limited by the following aspects. First, in the current work, cheese was investigated as a general subject instead of different cheese subtypes. The study with more accurate cheese subclassifications will offer a more precise and robust conclusion as different cheese subtypes vary in the health-associated nutrient components. Second, all the GWAS data analyzed originated from individuals of European descent which may impair the generalizability of the conclusion.

In general, our study firstly reported the inverse association between eating cheese and DR risk from a MR perspective. This finding implies that daily cheese intake may be regarded as a modifiable approach to decrease the DR risk.

226

227	Conflict of Interest
228	The authors declare no conflict of interest.
229	
230	Acknowledgement
231	We want to thank to the UK biobank and FinnGen project as well as the participants who generously
232	made the GWAS summary statistics of cheese intake and diabetic retinopathies publicly available. No
200 224	fund was obtained for this work.
204	Ethics Approval
235	Etines Approval: The used GWAS data were publicly available and approved by their corresponding institutions. A local
237	ethics approval for the current work is not required
238	curies approval for the current work is not required.
239	Data availability:
240	The GWAS data were publicly available and their sources were described appropriately in the
241	manuscript.
242	
243	μ-Biomedical Data Investigation Group:
244	Zenan Lin ¹ , Junhong Jiang ¹ , Di Hu ² , and Qi Zhang ³
245	¹ The Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School
246	of Medicine, Shanghai, 200080, China.
247	² The Department of Ophthalmology, Children's Hospital of Fudan University, No.399 Wanyuan Road,
248	Shanghai, 201102, China.
249	³ The Department of Neurology, The Affiliated Taizhou People's Hospital of Nanjing Medical
250	University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu,
251	225300, China.
252	
253	References
254	1. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes care 2003;26 Suppl
255	1:S99-s102.
256	2. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
257	3. Causes of blindness and vision impairment in 2020 and trends over 30 years, and
258	prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis
259	for the Global Burden of Disease Study. The Lancet Global health 2021;9:e144-e160.
260	4. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic

261 review. Jama 2007;298:902-16.

- 262 5. Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema
- 263 with prompt versus deferred laser treatment: three-year randomized trial results.
- 264 Ophthalmology 2012;119:2312-8.
- 265 6. Ojo O. Dietary Intake and Type 2 Diabetes. Nutrients 2019;11.
- 266 7. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes:
- dietary components and nutritional strategies. Lancet (London, England) 2014;383:1999-2007.
- 268 8. Dow C, Mancini F, Rajaobelina K, et al. Diet and risk of diabetic retinopathy: a systematic
- 269 review. 2018;33:141-156.
- 270 9. Díaz-López A, Babio N, Martínez-González MA, et al. Mediterranean Diet, Retinopathy,
- 271 Nephropathy, and Microvascular Diabetes Complications: A Post Hoc Analysis of a
- 272 Randomized Trial. Diabetes care 2015;38:2134-41.
- 273 10. Yan X, Han X, Wu C, et al. Does daily dietary intake affect diabetic retinopathy
- progression? 10-year results from the 45 and Up Study. 2020;104:1774-1780.
- 275 11. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
- inference in epidemiological studies. Human molecular genetics 2014;23:R89-98.
- 277 12. Cui Y, Si W, Zhu C. Alcohol Consumption and Mild Cognitive Impairment: A Mendelian
- 278 Randomization Study from Rural China. 2022;14.
- 279 13. Pedron S, Kurz CF, Schwettmann L, Laxy M. The Effect of BMI and Type 2 Diabetes on
- 280 Socioeconomic Status: A Two-Sample Multivariable Mendelian Randomization Study.
- 281 2021;44:850-852.

- 282 14. Manousaki D, Harroud A. Vitamin D levels and risk of type 1 diabetes: A Mendelian
- 283 randomization study. 2021;18:e1003536.
- 284 15. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal
- inference across the human phenome. Elife 2018;7.
- 286 16. Elsworth B, Lyon M, Alexander T, et al. The MRC IEU OpenGWAS data infrastructure.
- 287 bioRxiv 2020:2020.08.10.244293.
- 288 17. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
- genetic variants using summarized data. Genet Epidemiol 2013;37:658-65.
- 290 18. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in
- 291 causal relationships inferred from Mendelian randomization between complex traits and
- diseases. Nature Genetics 2018;50:693-698.
- 293 19. Poppitt SD. Cow's Milk and Dairy Consumption: Is There Now Consensus for
- 294 Cardiometabolic Health? Front Nutr 2020;7:574725.
- 295 20. Sluijs I, Forouhi NG, Beulens JW, et al. The amount and type of dairy product intake and
- incident type 2 diabetes: results from the EPIC-InterAct Study. Am J Clin Nutr 2012;96:382-90.
- 297 21. Aune D, Norat T, Romundstad P, Vatten LJ. Dairy products and the risk of type 2 diabetes:
- 298 a systematic review and dose-response meta-analysis of cohort studies. Am J Clin Nutr
- 299 2013;98:1066-83.
- 300 22. von Post-Skagegård M, Vessby B, Karlström B. Glucose and insulin responses in healthy
- 301 women after intake of composite meals containing cod-, milk-, and soy protein. European
- 302 Journal of Clinical Nutrition 2006;60:949-954.

303	23.	Pittas AG.	Lau J.	Hu FB.	Dawson-Hugh	nes B.	The role of	i vitamin D) and calcium i	n type 2
-----	-----	------------	--------	--------	-------------	--------	-------------	-------------	-----------------	----------

- diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017-29.
- 305 24. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J
- 306 Clin Nutr 2011;65:1005-15.
- 307 25. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes:
- 308 meta-analysis of prospective cohort studies. Diabetes Care 2011;34:2116-22.
- 309 26. Volpe SL. Magnesium, the metabolic syndrome, insulin resistance, and type 2 diabetes
- 310 mellitus. Crit Rev Food Sci Nutr 2008;48:293-300.
- 311 27. Mozaffarian D, Cao H, King IB, et al. Trans-palmitoleic acid, metabolic risk factors, and
- anew-onset diabetes in U.S. adults: a cohort study. Ann Intern Med 2010;153:790-9.
- 313 28. Yan X, Han X, Wu C, et al. Does daily dietary intake affect diabetic retinopathy
- 314 progression? 10-year results from the 45 and Up Study. Br J Ophthalmol 2020;104:1774-1780.
- 315 29. Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk
- 316 factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol
- 317 2016;44:260-77.
- 30. Sharafedtinov KK, Plotnikova OA, Alexeeva RI, et al. Hypocaloric diet supplemented with
 probiotic cheese improves body mass index and blood pressure indices of obese hypertensive
 patients--a randomized double-blind placebo-controlled pilot study. Nutrition journal
 2013; 12:138.
- 322 31. Hu MJ, Tan JS, Gao XJ, Yang JG, Yang YJ. Effect of Cheese Intake on Cardiovascular
- 323 Diseases and Cardiovascular Biomarkers. Nutrients 2022;14.

13

324	32. Schmidt KA, Cromer G, Burhans MS, et al. Impact of low-fat and full-fat dairy foods on
325	fasting lipid profile and blood pressure: exploratory endpoints of a randomized controlled trial.
326	2021;114:882-892.

- 327 33. O'Connor S, Turcotte AF, Gagnon C, Rudkowska I. Increased Dairy Product Intake
- 328 Modifies Plasma Glucose Concentrations and Glycated Hemoglobin: A Systematic Review
- 329 and Meta-Analysis of Randomized Controlled Trials. Advances in nutrition (Bethesda, Md)
- 330 2019;10:262-279.
- 331 34. Hjerpsted J, Leedo E, Tholstrup T. Cheese intake in large amounts lowers
- 332 LDL-cholesterol concentrations compared with butter intake of equal fat content. The
- American journal of clinical nutrition 2011;94:1479-84.
- 334 35. Brassard D, Tessier-Grenier M, Allaire J, et al. Comparison of the impact of SFAs from
- 335 cheese and butter on cardiometabolic risk factors: a randomized controlled trial. The American
- journal of clinical nutrition 2017;105:800-809.
- 337 36. Thorning TK, Raziani F, Bendsen NT, Astrup A. Diets with high-fat cheese, high-fat meat,
- 338 or carbohydrate on cardiovascular risk markers in overweight postmenopausal women: a
- randomized crossover trial. 2015;102:573-81.
- 340 37. Vasconcelos FM, Silva HLA, Poso SMV, et al. Probiotic Prato cheese attenuates cigarette
- 341 smoke-induced injuries in mice. Food research international (Ottawa, Ont) 2019;123:697-703.
- 342 38. Tognocchi M, Conte M. Supplementation of Enriched Polyunsaturated Fatty Acids and
- 343 CLA Cheese on High Fat Diet: Effects on Lipid Metabolism and Fat Profile. 2022;11.
- 344 39. Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of

- 345 diabetic retinopathy. Progress in retinal and eye research 2016;51:156-86.
- 346 40. Bryl A, Falkowski M, Zorena K. The Role of Resveratrol in Eye Diseases-A Review of the
- 347 Literature. 2022;14.
- 348
- 349
- 350